Publications in collaboration with researchers from Charité (14)

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  3. European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours

    The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381

2022

  1. Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

    Clinical Lymphoma, Myeloma and Leukemia

  2. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

    ESMO Open, Vol. 7, Núm. 2

2020

  1. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis

    The Lancet Haematology, Vol. 7, Núm. 10, pp. e746-e755

  2. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 8, pp. 1940-1951

2015

  1. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

2009

  1. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network

    Annals of Oncology, Vol. 20, Núm. 8, pp. 1303-1317

2008

  1. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    Leukemia, Vol. 22, Núm. 2, pp. 414-423

2006

  1. A practical update on the use of bortezomib in the management of multiple myeloma

    Oncologist, Vol. 11, Núm. 1, pp. 51-61

  2. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: Analysis of outcomes reported to an international registry

    Journal of Intensive Care Medicine, Vol. 21, Núm. 1, pp. 27-39

2003

  1. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial

    Journal of Thrombosis and Haemostasis, Vol. 1, Núm. 3, pp. 425-432